Immune Complex-mediated Membranoproliferative Glomerulonephritis

• CLINICAL_TRIALS research · 2026-04-22
  Clinical Trial Update: Chinese Adults With Kidney Disease [Phase 2]

  ADARx Pharmaceuticals is conducting a Phase 2 trial in Chinese adults with immunoglobulin A nephropathy, C3 glomerulopathy, or immune comple…

• CLINICAL_TRIALS research · 2026-04-14
  Clinical Trial Update: Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN [Phase 3]

  Phase 3 trial update on iptacopan for C3 glomerulopathy and immune-complex-mediated membranoproliferative glomerulonephritis; recruitment is…

• CLINICAL_TRIALS approval · 2025-11-06
  Clinical Trial Update: C3G/Primary IC-MPGN EAP

  Apellis' pegylated C3 inhibitor pegcetacoplan has gained marketing approval for C3 glomerulopathy and immune complex–mediated MPGN as part o…

• CLINICAL_TRIALS research · 2025-02-28
  Clinical Trial Update: Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study

  Clinical trial update describing a hybrid retrospective-prospective study of outcomes in C3 glomerulopathy and immune complex-mediated membr…

• CLINICAL_TRIALS trial_result · 2025-02-07
  Clinical Trial Update: Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN [Phase 2]

  Phase 2 trial assessing pegcetacoplan for post-transplant recurrence of C3 glomerulopathy and immune complex-mediated MPGN has completed wit…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2025-01-22
  Clinical Trial Update: A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases [Phase 2]

  A Phase 2 clinical trial of SGB-9768 for complement-mediated kidney diseases, including IgA nephropathy and C3 glomerulopathy, has not yet s…

• CLINICAL_TRIALS trial_result · 2021-07-13
  Clinical Trial Update: A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN [Phase 2]

  Phase 2 trial assessing danicopan effects on C3 levels in participants with C3 glomerulopathy or IC-MPGN; the study is completed with result…